nach oben

International Journal of Mental Health and Addiction

Erschienen in:

18.11.2016 | Original Article

Stigma and Social Support in Pharmaceutical Opioid Treatment Populations: a Scoping Review

verfasst von: Sasha Cooper, Suzanne Nielsen

Erschienen in: International Journal of Mental Health and Addiction | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Pharmaceutical opioid (PO) use and harms are increasing dramatically. Treatment related stigma may present as a treatment barrier for people who use PO. Additionally, differences in social support between PO and other opioid treatment populations may positively influence treatment outcomes. A scoping methodology was utilised to map current knowledge, with searches performed in Medline, PsycINFO and Embase. Eligibility criteria required articles related to stigma and social support in treatment for PO use. The search identified 44 relevant articles. Stigma themes included individual perceptions of opioid dependence, community perceptions of opioid dependence, blame as a stigmatising factor, language surrounding opioid use, and treatment experience. Social support themes included family as support, web-based support, friends as support, partners as support and social network therapy. Limited literature was found focussing specifically on stigma and social support in people who use PO, highlighting that this is an important area for future work.

Anstice, S., Strike, C. J., & Brands, B. (2009). Supervised methadone consumption: client issues and stigma. Substance Use & Misuse, 44(6), 794–808. doi:10.1080/10826080802483936.CrossRef

Arksey, H., & O’Malley, L. (2005). Scoping studies: towards a methodological framework. International Journal of Social Research Methodology, 8(1), 19–32.CrossRef

Barry, C. L., McGinty, E. E., Pescosolido, B. A., & Goldman, H. H. (2014). Stigma, discrimination, treatment effectiveness, and policy: public views about drug addiction and mental illness. Psychiatric Services, 65(10), 1269–1272. doi:10.1176/appi.ps.201400140.CrossRefPubMedPubMedCentral

Beattie, M., & Longabough, R. (1999). General and alcohol-specific social support following treatment. Addictive Behaviors, 24(5), 593–606.CrossRefPubMed

Berterame, S., Erthal, J., Thomas, J., Fellner, S., Vosse, B., Clare, P., et al. (2016). Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet, 387(10028), 1644–1656. doi:10.1016/s0140-6736(16)00161-6.CrossRefPubMed

Best, D. W., Ghufran, S., Day, E., Ray, R., & Loaring, J. (2008). Breaking the habit: a retrospective analysis of desistance factors among formerly problematic heroin users. Drug and Alcohol Review, 27(6), 619–624. doi:10.1080/09595230802392808.CrossRefPubMed

Blanch, B., Pearson, S. A., & Haber, P. S. (2014). An overview of the patterns of prescription opioid use, costs and related harms in Australia. British Journal of Clinical Pharmacology, 78(5), 1159–1166.CrossRefPubMedPubMedCentral

Brown, S. E., & Altice, F. L. (2014). Self-management of buprenorphine/naloxone among online discussion board users. Subst. Use Misuse, 49(8), 1017–1024.

Cooper, R. J. (2013). ‘I can’t be an addict. I am.’ Over-the-counter medicine abuse: a qualitative study. BMJ Open, 3(6). doi:10.1136/bmjopen-2013-002913.

Corrigan, P. W., Kuwabara, S. A., & O’Shaughnessy, J. (2009). The public stigma of mental illness and drug addiction. Journal of Social Work, 9(2), 139–147.CrossRef

Costantini, M., Wermuth, L., Sorensen, J., & Lyons, J. (1992). Family functioning as a predictor of progress in substance abuse treatment. Journal of Substance Abuse Treatment, 9(4), 331–335.CrossRefPubMed

Crawford, S. (2013). Shouting through bullet-proof glass: some reflections on pharmacotherapy provision in one Australian clinic. International Journal of Drug Policy, 24(6), e14–e17. doi:10.1016/j.drugpo.2013.07.004.CrossRefPubMed

Daudt, H. M., Van Mossel, C., & Scott, S. J. (2013). Enhancing the scoping study methodology: a large, inter-professional team’s experience with Arksey and O’Malley’s framework. BMC Medical Research Methodology, 13(1), 48.CrossRefPubMedPubMedCentral

Day, E., Copello, A., Karia, M., Roche, J., Grewal, P., George, S., et al. (2013). Social network support for individuals receiving opiate substitution treatment and its association with treatment progress. European Addiction Research, 19(4), 211–221. doi:10.1159/000343827.CrossRefPubMed

Deering, D., Horn, J., & Frampton, C. M. (2012). Clients’ perceptions of opioid substitution treatment: an input to improving the quality of treatment. International Journal of Mental Health Nursing, 21(4), 330–339. doi:10.1111/j.1447-0349.2011.00795.x.CrossRefPubMed

DeFlavio, J. R., Rolin, S. A., Nordstrom, B. R., & Kazal Jr., L. A. (2015). Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural and Remote Health, 15, 3019.PubMed

Donaldson, C. D., Nakawaki, B., & Crano, W. D. (2015). Variations in parental monitoring and predictions of adolescent prescription opioid and stimulant misuse. Addictive Behaviors, 45, 14–21. doi:10.1016/j.addbeh.2015.01.022.CrossRefPubMed

Earnshaw, V., Smith, L., & Copenhaver, M. (2013). Drug addiction stigma in the context of methadone maintenance therapy: an investigation into understudied sources of stigma. International Journal of Mental Health and Addiction, 11(1), 110–122. doi:10.1007/s11469-012-9402-5.CrossRefPubMed

Esquibel, A. Y., & Borkan, J. (2014). Doctors and patients in pain: conflict and collaboration in opioid prescription in primary care. Pain, 155(12), 2575–2582. doi:10.1016/j.pain.2014.09.018.CrossRefPubMed

Fischer, B., Chin, A. T., Kuo, I., Kirst, M., & Vlahov, D. (2002). Canadian illicit opiate users’ views on methadone and other opiate prescription treatment: an exploratory qualitative study. Substance Use and Misuse, 37(4), 495–522. doi:10.1081/JA-120002807.CrossRefPubMed

Fischer, B., Jones, W., & Rehm, J. (2013). High correlations between levels of consumption and mortality related to strong prescription opioid analgesics in British Columbia and Ontario, 2005-2009. Pharmacoepidemiology and Drug Safety, 22(4), 438–442. doi:10.1002/pds.3404.CrossRefPubMed

Galanter, M., Dermatis, H., Glickman, L., Maslansky, R., Sellers, M., Neumann, E., & Rahman-Dujarric, C. (2004). Network therapy: decreased secondary opioid use during buprenorphine maintenance. Journal of Substance Abuse Treatment, 26(4), 313–318.CrossRefPubMed

Gidman, W., & Coomber, R. (2014). Contested space in the pharmacy: public attitudes to pharmacy harm reduction services in the west of Scotland. Research in Social & Administrative Pharmacy, 10(3), 576–587. doi:10.1016/j.sapharm.2013.07.006.CrossRef

Goehl, L., Nunes, E., Quitkin, F., & Hilton, I. (1993). Social networks and methadone treatment outcome: the costs and benefits of social ties. The American Journal of Drug and Alcohol Abuse, 19(3), 251–262.CrossRefPubMed

Goginenia, A., Stein, M. D., & Friedmann, P. D. (2001). Social relationships and intravenous drug use among methadone maintenance patients. Drug and Alcohol Dependence, 64(1), 47–53.CrossRef

Harris, J., & McElrath, K. (2012). Methadone as social control: institutionalized stigma and the prospect of recovery. Qualitative Health Research, 22(6), 810–824. doi:10.1177/1049732311432718.CrossRefPubMed

Havassy, B. E., Hall, S. M., & Wasserman, D. A. (1991). Social support and relapse: commonalities among alcoholics, opiate users, and cigarette smokers. Addictive Behaviors, 16(5), 235–246.CrossRefPubMed

Holliday, S. M., Magin, P. J., Dunbabin, J. S., Ewald, B. D., Henry, J. M., Goode, S. M., et al. (2012). Waiting room ambience and provision of opioid substitution therapy in general practice. Medical Journal of Australia, 196(6), 391–394. doi:10.5694/mja11.11338.CrossRefPubMed

Hollingworth, S. A., Gray, P. D., Hall, W. D., & Najman, J. M. (2015). Opioid analgesic prescribing in Australia: a focus on gender and age. Pharmacoepidemiology and Drug Safety, 24(6), 628–636.CrossRefPubMed

Kelly, S. M., O’Grady, K. E., Schwartz, R. P., Peterson, J. A., Wilson, M. E., & Brown, B. S. (2010). The relationship of social support to treatment entry and engagement: the community assessment inventory. Substance Abuse, 31(1), 43–52. doi:10.1080/08897070903442640.CrossRefPubMedPubMedCentral

Kidorf, M., Brooner, R. K., & King, V. L. (1997). Motivating methadone patients to include drug-free significant others in treatment: a behavioral intervention. Journal of Substance Abuse Treatment, 14(1), 23–28.CrossRefPubMed

Kimber, J., Larney, S., Hickman, M., Randall, D., & Degenhardt, L. (2015). Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet Psychiatry., 2(10), 901–908.CrossRefPubMed

Kissin, I. (2013). Long-term opioid treatment of chronic nonmalignant pain: unproven efficacy and neglected safety? Journal of Pain Research, 6, 513–529. doi:10.2147/JPR.S47182.CrossRefPubMedPubMedCentral

Kosten, T. R., Jalali, B., Steidl, J. H., & Kleber, H. D. (1987). Relationship of marital structure and interactions to opiate abuse relapse. The American Journal of Drug and Alcohol Abuse, 13(4), 387–399.CrossRefPubMed

Levac, D., Colquhoun, H., & O’Brien, K. K. (2010). Scoping studies: advancing the methodology. Implementation Science, 5(69). doi:10.1186/1748-5908-5-69.

Ling, W., Mooney, L., & Hillhouse, M. (2011). Prescription opioid abuse, pain and addiction: clinical issues and implications. Drug and Alcohol Review, 30(3), 300–305. doi:10.1111/j.1465-3362.2010.00271.x.CrossRefPubMedPubMedCentral

Livingston, J. D., Milne, T., Fang, M. L., & Amari, E. (2012). The effectiveness of interventions for reducing stigma related to substance use disorders: a systematic review. Addiction, 107(1), 39–50. doi:10.1111/j.1360-0443.2011.03601.x.CrossRefPubMedPubMedCentral

Loffreda, A., Falcone, G., Motola, G., Mazzeo, F., Iacobelli, M., Ferrari, P., & Rossi, F. (2003). Use of naltrexone for the treatment of opiate addiction in Campania, Italy: the role of family. Journal of Substance Use, 8(3), 182–185.CrossRef

Maarefvand, M., Eghlima, M., Rafiey, H., Rahgozar, M., Tadayyon, N., Deilamizadeh, A., & Ekhtiari, H. (2015). Community-based relapse prevention for opiate dependents: a randomized community controlled trial. Community Mental Health Journal, 51(1), 21–29. doi:10.1007/s10597-014-9772-1.CrossRefPubMed

Mak, W. W. S., Poon, C. Y. M., Pun, L. Y. K., & Cheung, S. F. (2007). Meta-analysis of stigma and mental health. Social Science & Medicine, 65(2), 245–261. doi:10.1016/j.socscimed.2007.03.015.CrossRef

Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane database of systematic reviews, CD002207.

McLellan, A. T., Arndt, I. O., Metzger, D. S., Woody, G. E., & O’Brien, C. P. (1993). The effects of psychosocial services in substance abuse treatment. JAMA, 269(15), 1953–1959.CrossRefPubMed

McMurphy, S., Shea, J., Switzer, J., & Turner, B., J. (2006). Clinic-based treatment for opioid dependence: a qualitative inquiry. American Journal of Health Behavior, 544(54).

Murphy, S., & Irwin, J. (1992). "living with the dirty secret": problems of disclosure for methadone maintenance clients. Journal of Psychoactive Drugs, 24(3), 257–264.CrossRefPubMed

Nielsen, S., Cameron, J., & Pahoki, S. (2010). Over the counter codeine dependence. Retrieved from Melbourne:

Nielsen, S., Bruno, R., Lintzeris, N., Fischer, J., Carruthers, S., & Stoove, M. (2011). Pharmaceutical opioid analgesic and heroin dependence: how do treatment-seeking clients differ in Australia? Drug and Alcohol Review, 30(3), 291–299. doi:10.1111/j.1465-3362.2011.00302.x.CrossRefPubMed

Nielsen, S., Hillhouse, M., Mooney, L., Ang, A., & Ling, W. (2015a). Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users. Journal of Substance Abuse Treatment, 48(1), 70–76. doi:10.1016/j.jsat.2014.06.006.CrossRefPubMed

Nielsen, S., Roxburgh, A., Bruno, R., Lintzeris, N., Jefferson, A., & Degenhardt, L. (2015b). Changes in non-opioid substitution treatment episodes for pharmaceutical opioids and heroin from 2002 to 2011. Drug and Alcohol Dependence, 149, 212–219. doi:10.1016/j.drugalcdep.2015.02.004.CrossRefPubMed

Nielsen, S., Larance, B., Degenhardt, L., Gowing, L., Kehler, C., & Lintzeris, N. (2016). Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane database of systematic reviews, In Press(Accepted 220416).

O’Farrell, T. J., Murphy, M., Alter, J., & Fals-Stewart, W. (2010). Behavioral family counseling for substance abuse: a treatment development pilot study. Addictive Behaviors, 35(1), 1–6. doi:10.1016/j.addbeh.2009.07.003.CrossRefPubMed

Orizio, G., Schulz, P., Gasparotti, C., Caimi, L., & Gelatti, U. (2010). The world of e-patients: a content analysis of online social networks focusing on diseases. Telemed J E Health, 16(10):1060–6. doi:10.1089/tmj.2010.0085.

Paulozzi, L. J. (2012). Prescription drug overdoses: a review. Journal of Safety Research, 43(4), 283–289. doi:10.1016/j.jsr.2012.08.009.CrossRefPubMed

Powers, M. B., Vedel, E., & Emmelkamp, P. M. (2008). Behavioral couples therapy (BCT) for alcohol and drug use disorders: a meta-analysis. Clinical Psychology Review, 28(6), 952–962.CrossRefPubMed

Rehm, J. (2002). The role of consumers. Reflection on the possibilities and limits of user interviews in opiate addiction treatment. Substance Use and Misuse, 37(4), 533–536. doi:10.1081/JA-120002809.CrossRefPubMed

Roxburgh, A. a. B., L. (2015). Accidental drug-induced deaths due to opioids in Australia, 2011. Retrieved from Sydney:

Ruetsch, C., Tkacz, J., McPherson, T. L., & Cacciola, J. (2012). The effect of telephonic patient support on treatment for opioid dependence: outcomes at one year follow-up. Addictive Behaviors, 37(5), 686–689. doi:10.1016/j.addbeh.2012.01.013.CrossRefPubMed

Scimeca, M., Savage, S., Portenoy, R., & Lowinson, J. (2000). Treatment of pain in methadone-maintained patients. Mount Sinai Journal of Medicine, 67(5–7).

Skinner, M. L., Haggerty, K. P., Fleming, C. B., Catalano, R. F., & Gainey, R. R. (2011). Opiate-addicted parents in methadone treatment: long-term recovery, health, and family relationships. Journal of Addictive Diseases, 30(1), 17–26.CrossRefPubMedPubMedCentral

Sohler, N. L., Weiss, L., Egan, J. E., Lopez, C. M., Favaro, J., Cordero, R., & Cunningham, C. O. (2013). Consumer attitudes about opioid addiction treatment: a focus group study in New York City. Journal of Opioid Management, 9(2), 111–119.CrossRefPubMedPubMedCentral

Soyez, V., De Leon, G., Broekaert, E., & Rosseel, Y. (2006). The impact of a social network intervention on retention in Belgian therapeutic communities: a quasi-experimental study. Addiction, 101(7), 1027–1034. doi:10.1111/j.1360-0443.2006.01441.x.CrossRefPubMed

Substance Abuse and Mental Health Services Administration (2010). Substance abuse treatment admissions involving abuse of pain relievers: 1998 and 2008. Substance Abuse and Mental Health Services Administration (SAMHSA): Office of Applied Studies.

Tomori, C., Go, V. F., Tuan le, N., Huong, N. M., Binh, N. T., Zelaya, C. E., et al. (2014). "in their perception we are addicts": social vulnerabilities and sources of support for men released from drug treatment centers in Vietnam. International Journal of Drug Policy, 25(5), 897–904. doi:10.1016/j.drugpo.2014.04.012.CrossRefPubMedPubMedCentral

Warren, J. I., Stein, J. A., & Grella, C. E. (2007). Role of social support and self-efficacy in treatment outcomes among clients with co-occurring disorders. Drug and Alcohol Dependence, 89(2–3), 267–274.CrossRefPubMedPubMedCentral

Woods, J. S., & Joseph, H. (2012). Reducing stigma through education to enhance medication-assisted recovery. Journal of Addictive Diseases, 31(3), 226–235.CrossRefPubMed

Woods, J. S., & Joseph, H. (2015). Stigma from the viewpoint of the patient. Journal of Addictive Diseases, 34(2–3), 238–247. doi:10.1080/10550887.2015.1059714.CrossRefPubMed

Titel: Stigma and Social Support in Pharmaceutical Opioid Treatment Populations: a Scoping Review
verfasst von: Sasha Cooper
Suzanne Nielsen
Publikationsdatum: 18.11.2016
Verlag: Springer US
Erschienen in: International Journal of Mental Health and Addiction / Ausgabe 2/2017
Print ISSN: 1557-1874
Elektronische ISSN: 1557-1882
DOI: https://doi.org/10.1007/s11469-016-9719-6

Neu im Fachgebiet Psychiatrie

23.04.2024 | Depression antepartal oder postpartal | Nachrichten

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Stigma and Social Support in Pharmaceutical Opioid Treatment Populations: a Scoping Review

Abstract

Neu im Fachgebiet Psychiatrie

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Psychiatrie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Problematic Gaming Behaviour in Finnish Adolescents and Young Adults: Relation to Game Genres, Gaming Motives and Self-Awareness of Problematic Use

Investigating Gender Differences on the Age of Suspicion of Children with Hearing Loss in Iran

Self-Management Strategies of Life, Positive Youth Development and Academic Buoyancy: a Causal Model

University Student Attitudes Toward Illicit Drug Use and Trafficking in Russia

Erratum to: Humanistic Education and students’ Educational Motivation in Tehran Primary Schools

Screening Tools for Technological Addictions: A Proposal for the Strategy of Mental Health

Neu im Fachgebiet Psychiatrie

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Psychiatrie